Pay around $49*/month depending on insurance coverage.
For a simple monthly payment, the Flex program offers a package which includes the MiniMed™ 670G pump, the enhanced Guardian™ Link 3 transmitter and a 3-month supply of Guardian™ Sensor 3, infusion sets and reservoirs.
Call today to learn more about your monthly cost to start using the MiniMed™ 670G system.
If you choose to take part in Flex, we will split up your out-of-pocket costs into monthly payments.
The MiniMed™ 670G system with SmartGuard™ technology automatically adapts to your unique insulin needs every five minutes to help stabilize your glucose.§
Just like how a thermostat adjusts to keep the temperature at a desired level, the
The amount you will pay with Flex is calculated by dividing your total out-of-pocket responsibility by 48 and adding the $6 service fee. Your total coinsurance amount is dependent on your insurance coverage.
Flex payments cover your out-of-pocket cost for a MiniMed™ 670G pump and starter kit. The starter kit includes a Guardian™ Link 3 transmitter and a 3-month supply of the following items: sensors, infusion sets, and reservoirs.
Flex payments do not include ongoing supplies beyond (or after) the first 90 days. To continue using pump therapy, patients must purchase additional transmitters, sensors, infusion sets, and reservoirs separately.
* $49/month estimate is calculated based on average out-of-pocket cost paid over 48 months. Monthly payments include a $6/month service fee. Final cost may be higher or lower than $49/month depending on individual insurance.
§ Refers to Auto Mode. Individual results may vary. Some interaction required.
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
© Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.